Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEER: Pembrolizumab + Exemestane + Leuprolide in Breast Cancer
NCT02990845Phase 2Terminated
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2017
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by National Taiwan University Hospital. Started Sep 2017; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02990845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990845.